ライブラリ登録: Guest
Critical Reviews™ in Physical and Rehabilitation Medicine

年間 4 号発行

ISSN 印刷: 0896-2960

ISSN オンライン: 2162-6553

SJR: 0.141 SNIP: 0.129 CiteScore™:: 0.6 H-Index: 18

Indexed in

A Review of the Current State of Management and Post-Recovery Rehabilitation of COVID-19

巻 32, 発行 2, 2020, pp. 97-109
DOI: 10.1615/CritRevPhysRehabilMed.2020034616
Get accessGet access

要約

In all countries, COVID-19 has had a profound impact on society in general and on healthcare systems in particular. Its route of transmission is similar to that of SARS-CoV and MERS-CoV, and it spreads through respiratory droplets and direct physical contact. It displays greater infectivity rates than the two recent viral outbreaks (SARS and MERS), and early epide-miological studies reveal lower fatality rates. Elderly and multimorbid persons are at the highest risk of developing complications and death. Although men and women are thought to be at equal risk for COVID-19, more men than women are dying, presumably due to sex-based immunological differences and lifestyle factors such as smoking. N95 respirators are thought to be more effective in preventing viral transmission than surgical masks, but the evidence is limited and inconsistent. The current clinical management strategy of COVID-19 is the same as acute respiratory distress syndrome (ARDS). Novel treatments and therapies such as the use of plasmapheresis, chloroquine, hydroxychloroquine, and remdesivir have shown promising results in clinical trials for treating COVID-19. The roles of physical rehabilitation and medicine are expected to increase because postrecovery COVID-19 patients are experiencing cardiovascular, neurological, psychological, and cognitive sequalae. Innovative management strategies are needed to limit the spread of disease and to protect vulnerable persons. Significant evidence indicates that the use of telerehabilitation reduces hospitalizations and cardiac events compared to regular care. Actions are needed to prevent deconditioning in rehabilitation patients, and respiratory therapy practices will require close attention to reduce the dispersion of air droplets.

参考
  1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.

  2. Government of Canada. Coronavirus disease (COVID-19): Symptoms and treatment. 2020. Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/ symptoms.html.

  3. McNeil Jr DG. Mask hoarders may raise risk of a Coronavirus outbreak in the U.S. The New York Times. January 29, 2020.

  4. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): How to protect yourself and others [Cited May 25, 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.

  5. Worldometers [Internet]. COVID-19 coronavirus pandemic [Cited May 25, 2020]. 2020. Available from: https://www.worldometers.info/coronavirus/.

  6. COVID-19 in the USA: A question of time. Lancet. 2020;395(10232):1229.

  7. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly. 2020;2(8):113-22.

  8. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):185-88 (in Chinese).

  9. Chan-Yeung M, Xu RH. SARS: Epidemiology. Respirology. 2003;8(Suppl):S9-S14.

  10. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int J Epidemiol. 2020 Feb 22. Epub ahead of print.

  11. COVID C, Team R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-46.

  12. Weeks C. Between 30 and 70 percent of Canadians could become infected with coronavirus, Patty Hajdu says. The Globe Mail. March 11, 2020.

  13. Sutherland JM, Crump RT. Alternative level of care: Canada's hospital beds, the evidence and options. Healthcare Policy. 2013 Aug;9(1):26-34.

  14. Singer BD, Corbridge TC. Basic invasive mechanical ventilation. South Med J. 2009 Dec;102(12): 1238-45.

  15. Mohlenkamp S, Thiele H. Ventilation of COVID-19 patients in intensive care units. Herz. 2020 Apr 20:1-3. Epub ahead of print.

  16. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2).

  17. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.

  18. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Version 2. Crit Care. 2020 Apr 2;24(1):128.

  19. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-36. Epub ahead of print.

  20. Loeb M, Dafoe N, Mahony J, John M, Sarabia A, Glavin V, Webby R, Smieja M, Earn DJ, Chong S, Webb A. Surgical mask vs. N95 respirator for preventing influenza among health care workers: A randomized trial. JAMA. 2009;302(17):1865-71.

  21. Lai AC, Poon CK, Cheung AC. Effectiveness of facemasks to reduce exposure hazards for airborne infections among general populations. J R Soc Interf. 2012 May 7;9(70):938-48.

  22. Chughtai AA, Stelzer-Braid S, Rawlinson W, Pontivivo G, Wang Q, Pan Y, Zhang D, Zhang Y, Li L, MacIntyre CR. Contamination by respiratory viruses on outer surface of medical masks used by hospital healthcare workers. BMC Infect Dis. 2019 Jun 3;19(1):491.

  23. Centers for Disease Control and Prevention [Internet]. Interim infection prevention and control recommendations for patients with suspected or confirmed Coronavirus disease 2019 (COVID-19) in healthcare settings [Cited May 15, 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.

  24. Choon-Huat Koh G, Hoenig H. How should the rehabilitation community prepare for 2019-nCoV? Arch Phys Med Rehabil. 2020 Mar 16:S0003-9993(20)30153-2. Epub ahead of print.

  25. Sarfo FS, Ulasavets U, Opare-Sem OK, Ovbiagele B. Tele-rehabilitation after stroke: An updated systematic review of the literature. J Stroke Cerebrovasc Dis. 2018;27:2306-18.

  26. Thomas E, Gallagher R, Grace SL. Future-proofing cardiac rehabilitation: Transitioning services to tele-health during COVID-19. Eur J Prev Cardiol. 2020 Apr 23:2047487320922926. Epub ahead of print.

  27. Kramer A, Gollhofer A, Armbrecht G, Felsenberg D, Gruber M. How to prevent the detrimental effects of two months of bed-rest on muscle, bone and cardiovascular system: An RCT. Sci Rep. 2017;7(1):13177.

  28. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020;104:246-51.

  29. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300.

  30. Carda S, Invernizzi M, Bavikatte G, Bensmail D, Bianchi F, Deltombe T, Draulans N, Esquenazi A, Francisco GE, Gross R, Jacinto LJ. The role of physical and rehabilitation medicine in the COVID-19 pandemic: The clinician's view. Ann Phys Rehabil Med. 2020 Apr 18:S1877-0657(20)30076-2. Epub ahead of print.

  31. Sheehy LM. Considerations for postacute rehabilitation for survivors of COVID-19. JMIR Public Health Surveill. 2020 May 8;6(2):e19462.

  32. Zhao HM, Xie YX, Wang C. Recommendations for respiratory rehabilitation in adults with COVID-19. Chin Med J (Engl). 2020 Apr 9. Epub ahead of print.

  33. Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, Hodgson C, Jones AY, Kho ME, Moses R, Ntoumenopoulos G. Physiotherapy management for COVID-19 in the acute hospital setting: Clinical practice recommendations. J Physiother. 2020 Apr;66(2):73-82.

  34. Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A, D'Abrosca F, Del Monaco C, Gaudellio G, Paneroni M, Privitera E. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: A Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Disease. 2020 Mar 26;90(1):1285.

  35. Severin R, Arena R, Lavie CJ, Bond S, Phillips SA. Respiratory muscle performance screening for infectious disease management following COVID-19: A highly pressurized situation. Am J Med. 2020 Apr 25:S0002-9343(20)30347-8. Epub ahead of print.

  36. Christopher M. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. medRxiv. 2020.03.27.20043752; doi: 10.1101/ 2020.03.27.20043752.

  37. Jewell NP, Lewnard JA, Jewell BL. Caution warranted: Using the institute for health metrics and evaluation model for predicting the course of the COVID-19 pandemic. Ann Intern Med. 2020 Apr 14:M20-1565. Epub ahead of print.

  38. Klein S, Flanagan K. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-38.

  39. Mezidi M, Guerin C. Effects of patient positioning on respiratory mechanics in mechanically ventilated ICU patients. Ann Transl Med. 2018;6(19):384.

  40. Hristara-Papadopoulou A, Tsanakas J, Diomou G, Papadopoulou O. Current devices of respiratory physiotherapy. Hippokratia. 2008;12(4):211-20.

  41. Maclntyre CR, Chughtai AA. A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the Community, Healthcare workers and Sick Patients. Int J Nurs Stud. 2020 Apr 30:103629. Epub ahead of print.

  42. Li FF, Yam JC. Low-concentration atropine eye drops for myopia progression. Asia Pac J Ophthalmol (Phila). 2019;8:360-365.

  43. Navel V, Beze S, Dutheil F. COVID-19, sweat, tears... and myopia? Clin Exp Optom. 2020 May 12. Epub ahead of print.

  44. Mehra MR, Desai SS, Ruschitzka F, Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet. 2020 May 22. Epub ahead of print.

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain